Benefits of two locally delivered agents on cytokine level in diabetic patients with chronic periodontitis.
Not Applicable
- Conditions
- Health Condition 1: K053- Chronic periodontitisHealth Condition 2: E119- Type 2 diabetes mellitus without complications
- Registration Number
- CTRI/2021/05/033474
- Lead Sponsor
- Panineeya Institute of Dental Sciences and Research centre
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients with Type II Diabetes Mellitus
HbA1c Levels more than 7 for uncontrolled Diabetics
HbA1c Levels 6 to 7 for controlled Diabetics
Patients with Chronic Periodontitis with 20 teeth present and having probing pocket depths greater than 5mm in one or more sites
Exclusion Criteria
Pregnant and lactating women
Smokers Patients with any auto immune or systemic disorder other than type II Diabetes
Use of Medicines or antibiotic 3 months before
History of periodontal treatment within 6 months
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Estimation of Interleukin 1 beta levels in the Gingival crevicular fluidTimepoint: Base line and 6 weeks after scaling and root planing
- Secondary Outcome Measures
Name Time Method Clinical parameters like plaque index Gingival index and probing pocket depths will be assesed with williams probeTimepoint: Base line 8 weeks and 12 weeks after scaling and root planing